NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
Updated: May 25, 2022
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monotherapy dose escalation (Part A) and monotherapy dose expansion (Part B).
Sponsor
Celgene
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04975399
Official Title: A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma
First Posted : July 23, 2021
Click here to see details on ClinicalTrials.gov
Drug: CC-92328
CC-92328
(DF 3001)
NK cell engager
TriNKET
tri-specific natural killer cell engager therapy
The Phase 1 clinical trial for the CC-92328 TriNKET is a first-in-human study which will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04975399).
Natural killer cell engagers in cancer immunotherapy
Locations
United States, Alabama
United States, Arizona
United States, Florida
United States, Maryland
United States, New York
United States, Wisconsin
Canada, Alberta
Canada, Nova Scotia
Canada, Ontario
Canada, Quebec
Europe
Spain
Sweden